Drop-down menu under Resources Tab with links to the following COVID-19 resources: ACEP's redesigned COVID-19 clinical alert page * Media Talking Points on COVID-19 * TMA's COVID-19 Resources
DSHS – RAC Operation Guidelines * DSHS – Information for Hospitals & Healthcare Professionals CMS Medicare Telemedicine Fact Sheet * HHS HIPAA Waiver for Telehealth CDC Updates PPE Policies, Reflects ACEP Input April 13, 2021COVID-19 TESTING SITES: • For POC tests, contact the vendor of interest and consult with it to see how best to access the desired testing. Abbott Labs ID NOW HOTLINE: (877) 441-7440; EMAIL: [email protected] • Consult with the laboratories that routinely perform your diagnostic services. Here is a list of private and hospital laboratories. • Refer your patient to a drive-thru screening location. • Refer your patient to a public health laboratory (make sure you meet the public health lab’s testing criteria) This information was gathered from TMA's testing FAQ (step 3). Additional information can be found on TMA's COVID-19 Resources page.
COVID-19 Texas Hospital Data Click Here for Current Hospital Data/Breakdown by Region What If My Patient Refuses to Wear a Mask? May 13, 2020 Notice and Compliance Requirements Concerning COVID-19 Minimum Standards of Safe PracticeSNS Requests Go Through RACs Here is how to contact your Regional Advisory Council to make requests of the Strategic National Stockpile. As a reminder DSHS announced the state has received a share of personal protective equipment from the Strategic National Stockpile. Note that the supplies are being distributed to areas where they are needed most. We are told the supplies are still very limited, for extreme circumstances and will be distributed through certain RACs. Telehealth Expansion for Medicare CMS today announced expanded Medicare telehealth coverage that will enable beneficiaries to receive a wider range of healthcare services from their doctors without having to travel to a healthcare facility. Beginning on March 6, 2020, CMS will temporarily pay clinicians to provide telehealth services for beneficiaries residing across the entire country. Telemedicine and Insurance Here is Gov. Abbott’s announcement waiving certain regulations and directing that the Texas Department of Insurance issue an emergency rule, all relating to telemedicine care for patients with state-regulated insurance plans to help doctors across Texas continue to treat their patients while mitigating the spread of COVID-19. The suspensions and emergency rule will work together to allow telemedicine visits for patients with state-regulated plans to be paid the same as in-office visits for insurance purposes.
Telemedicine and Controlled Substances The Drug Enforcement Administration has confirmed that telemedicine can now be used under the conditions outlined in the Controlled Substances Act under the public health emergency telemedicine exception to the Ryan Haight Act. DEA-registered prescribers may issue prescriptions for controlled substances via telemedicine without a prior in-person evaluation if the prescription is for a legitimate medical purpose, real-time two-way audio-video is used, and the practitioner is acting in accordance with state law. See more information on this coronavirus page under "telemedicine.” CDC Discontinuation of Isolation for Persons with COVID-19 Not in Healthcare SettingsUpdates as of July 20, 2020: A test-based strategy is no longer recommended to determine when to discontinue home isolation, except in certain circumstances. Time-since-illness-onset and time-since-recovery strategy (non-test-based strategy) See Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for 2019 Novel Coronavirus (2019-nCoV)for specimen collection guidance. For patients with severe illness, duration of isolation for up to 20 days after symptom onset may be warrented. Consider consultation with infection control experts. Individuals with laboratory-confirmed COVID-19 who have not had any symptoms may discontinue home isolation when at least 10 days have passed since the date of their first positive RT-PCR test for SARS-CoV-2 RNA, and have had no subsequent illness.j A summary of current evidence and rationale for these changes is described in the Duration of Isolation and Precautions for Adults with COVID-19. www.cdc.gov/coronavirus/2019-ncov/hcp/... ACEP's redesigned COVID-19 clinical alert pageWhat You Need to Know: PPE Resources – Respirators
PPE Resources – Don & Doff
What You Can Do:
What ACEP Is Doing:
Get Real-Time Support:
Join more than 2,200 ACEP members sharing strategies and getting peer support on our COVID-19 engagED community forum. In response to public health and safety concerns about the appropriateness of decontaminating certain respirators, the FDA is reissuing certain EUAs to specify which respirators are appropriate for decontamination. Based on the FDA's increased understanding of the performance and design of these respirators, the FDA has decided that certain respirators should not be decontaminated for reuse by health care personnel. For example, the FDA has learned from the CDC's NIOSH testing that authorized respirators manufactured in China may vary in their design and performance. As such, the FDA has determined that the available information does not support the decontamination of these respirators and has accordingly revised the relevant EUAs. In addition, the FDA is also revising relevant EUAs to no longer authorize decontamination or reuse of respirators that have exhalation valves. |